The Role of SGLT2i in Management of Moderate AS

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

Also called NCT06469645

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 2/3
Enrolled
  • 104 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06469645
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06469645. Randomized; no masking; primary purpose prevention. Start 2024-05-30 (actual); primary completion 2026-07-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Role of SGLT2i in Management of Moderate AS
Condition
Moderate Aortic Valve Stenosis
Intervention (Drug)
Empagliflozin 10 MG
Lead sponsor
University of East Anglia (class: other)
Collaborator
Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK) (class: other)

Record details

Record id
cardio:ct-nct06469645
Content hash
b4a11e73389362072425d4955fdec6a131b50ce20393801aa7157c7992ab8269